Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital

rss · SCMP 2026-11-18T06:00:08Z en
Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview. “Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said, adding that developing a...

This article is available on the publisher's site.

Read on SCMP

Knowledge Graph

Entities
Highlight